Treatment of aggressive basal cell carcinoma
with intralesional interferon: evaluation of efficacy by Mohs surgery.
To the Editor: We read with interest the article of Colvett et al (1) describing a patient with numerous basal cell carcinomas
on the lower extremity occurring in a linear distribution.
Existing topical therapies have proven suboptimal due to lack of efficacy, and the only approved oral therapy for BCC is approved for irresectable or locally metastatic basal cell carcinomas
and it has a significant side-effect profile.
Its initial description in 1960 by Gorlin and Goltz included the classic features of basal cell carcinoma
, odontogenic keratocysts, and bifid ribs.
Basal cell carcinoma
is the most common skin malignancy in the white population, accounting for approximately 75% of all nonmelanoma skin cancers in the United States.
Inappropriate activation or dysregulation of the Hedgehog pathway is believed to play a critical role in the proliferation and survival of certain cancer cells, including in basal cell carcinoma
and medulloblastoma as well as in colorectal, ovarian, pancreatic, small cell lung and breast cancers, among others.
A first basal cell carcinoma
quadrupled the relative risk for melanoma in men, tripled the risk for melanoma in women, and raised women's risk for lip cancer fivefold.
We describe the imaging findings in a 13-year-old boy with nevoid basal cell carcinoma
7, 2015 /PRNewswire/ -- Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company focused on developing innovative cancer therapeutics, today announced the first nodular Basal Cell Carcinoma
patient (nBCC) dosed with ASN-002 (an injectable immunotherapy) in a Phase 1/2a clinical study.
Basal Cell Carcinoma
(Basal Cell Epithelioma) - Pipeline Review, H1 2015 market research report provides an overview of the Basal Cell Carcinoma
(Basal Cell Epithelioma)'s therapeutic pipeline for H1 2015.
Contrary to our expectations, histologic examination was interpreted as a basal cell carcinoma
ALBUQUERQUE - The incidence of basal cell carcinoma
in Northern California rose by about 13% during 1998 through 2012, according to an analysis of more than 147,000 insured patients.
X-Men: Days of Future Past" actor Hugh Jackman recently revealed that he had once again removed basal cell carcinoma
from his nose, and urged his fans to use sunscreen before stepping out into the sun.
Novartis announced today that the pivotal trial of the investigational oral compound LDE225 (sonidegib) in advanced basal cell carcinoma
met its primary endpoint of demonstrating an objective response rate among patients within six months of treatment.
Hugh Jackman The actor had treatment for basal cell carcinoma